SetPoint Medical to Present Results From The U.S. Pilot Study in Rheumatoid Arthritis Patients at European Congress of Rheumatology (EULAR) 2019

NEXT STORY
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting
PREV STORY
Tempus Announces (TIME) Trial Service, a New Integrated Molecular Evaluation that Leverages Artificial Intelligence to Rapidly Match Cancer Patients to Clinical Trials
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medical Affairs Outsourcing Market Growth Sturdy at 11.2% CAGR to Outstrip $3,287.12 Million by 2027 – COVID-19 Impact and Global Analysis by TheInsightPartners.com

author_avatar
NASDAQ Market News

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

author_avatar
NASDAQ Market News

Heat Biologics Appoints Dr. John Prendergast to Board of Directors

DURHAM, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an ...

author_avatar
NASDAQ Market News